Opinion of the Transparency Council – tocilizumab

At its meeting on 29 July 2024, the Transparency Council adopted opinion No. 115/2024 on the inclusion in reimbursement of medicines containing the active substance tocilizumab for the off-label indication: treatment of patients with giant cell arteritis (GCA), in the framework of the drug programme B.75. ‘Treatment of patients with systemic vasculitis (ICD-10: M31.3, M31.5, M31.6, M31.7, M31.8)”

Publication on the list of opinions on active substances for off-label indications >>